Researchers developed the ATRIVIEW® platform to screen for molecules that promote differentiation neural stem cells (NSCs).
FILAMENT HEALTH ANNOUNCES CHANGE TO BOARD OF DIRECTORS | Psychedelic Invest
Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that Maureen O’Connell has stepped